Hematologic Malignancies

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

By

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

By

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

By

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

By

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

By

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

By

Why was the ESA APPRISE risk evaluation and mitigation strategy program discontinued?

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

By

Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.

Defibrotide an Effective Option for SOS/VOD in Patients Undergoing HSCT

Defibrotide an Effective Option for SOS/VOD in Patients Undergoing HSCT

By

Sinusoidal obstruction syndrome (or hepatic veno-occlusive disease), a complication observed in patients who undergo HSCT, is managed with defibrotide. In this study, investigators assessed its efficacy and patient response to therapy.

Complications and Management of Coagulation Disorders in Leukemia Patients

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA

By

This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

By

A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

By

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Combination of Western Care With Chinese Medicine Shows Potential in ITP

Combination of Western Care With Chinese Medicine Shows Potential in ITP

By

The pathogenesis of idiopathic thrombocytopenic purpura (ITP) may be associated with Th17 helper T cells.

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

By

The main cause of ITP remains unidentified; however, researchers suggest that certain polymorphisms in respective genes are potential factors for ITP.

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

By

A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.

Navigating Patients With Hematologic Cancers

Navigating Patients With Hematologic Cancers

By

An effective nurse navigator approach involves removing barriers to good care, such as differences in health care delivery systems, poor communication, and financial impediments.

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

By

A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

By

Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.

Eradication of Infection Improves Outcomes for <i>H Pylori+</i> patients with ITP

Eradication of Infection Improves Outcomes for H Pylori+ patients with ITP

By

Approximately 40% of ITP cases are caused by gram-negative H pylori infection; therefore, researchers sought to determine the effectiveness of infection eradication on platelet count in these patients.

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

By

A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

By

A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

By

MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.

Optimal Management of Myeloma With Bortezomib

Optimal Management of Myeloma With Bortezomib

By

In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

New Gene Mutations Associated with Erdheim-Chester Disease Could Improve Treatment Options

New Gene Mutations Associated with Erdheim-Chester Disease Could Improve Treatment Options

By

BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs